טוען...
Tolerance and Activity of Oxaliplatin with Protracted Topotecan Infusion In Patients With Previously Treated Ovarian Cancer. A phase I study
BACKGROUND: Topotecan 14-day infusion combined with cisplatin was highly active in ovarian cancer, but too myelosuppressive. We therefore sought to evaluate the feasibility of substituting oxaliplatin for cisplatin to improve safety. METHODS: Ovarian and primary peritoneal cancer patients, pre-treat...
שמור ב:
| Main Authors: | , , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2008
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3572735/ https://ncbi.nlm.nih.gov/pubmed/18191187 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2007.11.017 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|